Belatacept
- Generic Name
- Belatacept
- Brand Names
- Nulojix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 706808-37-9
- Unique Ingredient Identifier
- E3B2GI648A
- Background
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of t...
- Indication
For prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus.
- Associated Conditions
- Kidney Transplant Rejection
- Associated Therapies
- -
Belatacept in Heart Transplantation
- Conditions
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-10-31
- Target Recruit Count
- 66
- Registration Number
- NCT06478017
- Locations
- 🇺🇸
Cedars Sinai Heart Institute/ Cedars Sinai Medical (Site # 71146), Los Angeles, California, United States
🇺🇸Tampa General Hospital (Site # 71150), Tampa, Florida, United States
🇺🇸NYU Langone Health (Site # 71177), New York, New York, United States
Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 66
- Registration Number
- NCT06307808
- Locations
- 🇫🇷
Grenoble University Hospital, Grenoble, Aura, France
Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO>
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- University Hospital, Rouen
- Target Recruit Count
- 44
- Registration Number
- NCT06291077
Advancing Transplantation Outcomes in Children
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 200
- Registration Number
- NCT06055608
- Locations
- 🇺🇸
University of Alabama at Birmingham (Site # 71038), Birmingham, Alabama, United States
🇺🇸Children's Hospital of Los Angeles (Site #: 71036), Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center (Site #: 71026), Los Angeles, California, United States
Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.
- Conditions
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- University Hospital, Rouen
- Target Recruit Count
- 28
- Registration Number
- NCT05708534
Abatacept Conversion in Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 86
- Registration Number
- NCT04955366
- Locations
- 🇺🇸
Emory University Hospital (EUH), Atlanta, Georgia, United States
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 102
- Registration Number
- NCT04877288
- Locations
- 🇺🇸
Local Institution - 0038, Seattle, Washington, United States
🇺🇸Local Institution - 0045, Miami, Florida, United States
🇺🇸Local Institution - 0022, Hollywood, Florida, United States
Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 120
- Registration Number
- NCT04849533
- Locations
- 🇺🇸
The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT04786067
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Belatacept in De Novo Heart Transplantation
- Conditions
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 12
- Registration Number
- NCT04477629
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸Columbia University, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.